Chennai, April 28 (IANS) A team of Indian researchers has developed a new biosensor platform that can test and diagnose preeclampsia — is a life-threatening complication caused by hypertension — among pregnant women in 30 minutes.
Preeclampsia, which typically develops after 20 weeks of pregnancy, affects 2-8 per cent of pregnancies worldwide.
While traditional methods to detect preeclampsia are time-consuming, and require huge infrastructure and trained personnel, the new platform offers rapid, on-site, and affordable screening at an early stage. Timely treatment is crucial to minimise both maternal and neonatal morbidity and mortality rates.
The team led by the Indian Institute of Technology Madras (IIT) Madras, along with the Vellore Institute of Technology developed the Plasmonic Fibre Optic Absorbance Biosensor (P-FAB) technology using fibre optics sensor technology.
They focussed on Placental growth factor (PlGF) — an angiogenic blood biomarker used widely for the diagnosis of preeclampsia.
“The P-FAB technology was able to detect PlGF at a femtomolar level using polymethyl methacrylate (PMMA) based U-bent polymeric optical fiber (POF) sensor probes,” said Prof. V.V. Raghavendra Sai, Biosensors Laboratory, Department of Applied Mechanics and Biomedical Engineering, IIT Madras.
The ‘PlGF’ biomarker peaks at 28 to 32 weeks in normal pregnancy but in the case of women with pre-eclampsia, it decreases by 2 to 3 times after 28 weeks of pregnancy.
The new POF sensor probes could measure PlGF within 30 minutes using the P-FAB strategy. The clinical sample testing confirmed the accuracy, reliability, specificity, and sensitivity of the P-FAB-based POF sensor platform, thereby paving the way for cost-effective technology for PlGF detection and its potential for pre-eclampsia diagnosis.
“The biosensor platform developed by the research team is simple and reliable, paving the way for affordable diagnosis. It can also lead to increasing the test coverage of Placental growth factor (PlGF) biomarker tests, thereby resulting in a potential for a significant impact on the management of pre-eclampsia and towards reduction in the global burden of mortality and morbidity from preeclampsia,” Sai added.
The study, published in the reputed journal Biosensors and Bioelectronics, showed that the POF platform has potential applications for detecting other communicable and non-communicable diseases such as cancer, tuberculosis, Alzheimer’s, etc. It eliminates the use of harsh chemicals and utilises recyclable POF.
It can also be used in remote and resource-limited settings for preeclampsia diagnosis, said the researchers.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
